Dermatol. praxi. 2019;13(1):9-12 | DOI: 10.36290/der.2019.002

Treatment of moderate‑to‑severe

MUDr. Petra Brodská, Ph.D.
Dermatovenerologická klinika, FN Plzeň

Atopic dermatitis is a common, chronic, relapsing inflammatory skin disease. The complex of different interactions between individual genetic predisposition to atopic diseases (bronchial asthma, allergic rhino-conjunctivitis, and food or inhalant allergy), environmental factors, epidermal barrier dysfunction and abnormalities of the immune system are involved. The currently available therapeutics are limited. Over the last few years, new advances in the understanding of atopic dermatitis pathogenic mechanisms and inflammatory pathways have led to the identification of specific therapeutic targets and new molecules have been tested. Biological target treatment seems to be very promising in the management of moderate-to-severe atopic dermatitis.

Keywords: Atopic dermatitis, topical corticosteroids, topical calcineurin inhibitors, cyclosporine, dupilumab

Published: March 21, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Brodská P. Treatment of moderate‑to‑severe. Dermatol. praxi. 2019;13(1):9-12. doi: 10.36290/der.2019.002.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Štork J, Arenberger P, Pizinger K, et al. Dermatovenerologie. 1. vydání, Praha: Galén, 2008.
    2. Braun - Falco O, Plewig G, Wolf H, et al. Dermatology 3rd ed. Berlin: Springer-Verlag, 2009.
    3. Irvine AD, Mclean WH, Leung DY. Filaggrin mutations associated with skin and allergic diseases. N Engl J Med. 2011; 365(14): 1315-1327. Go to original source... Go to PubMed...
    4. Weidinger S, Klopp N, Rummler L, et al. Association of NOD1 polymorphisms with atopic eczema and related phenotypes. J Allergy Clin Immunol, 2005; 116(1): 177-184. Go to original source... Go to PubMed...
    5. Bieber T, Novak N. Pathogenesis of atopic dermatitis: new developments. Curr Allergy Asthma Rep. 2009; 9(4): 291-294. Go to original source... Go to PubMed...
    6. Tokura Y. Extrinsic and intrinsic types of atopic dermatitis. J Dermatol Sci. 2010; 58(1): 1-7. Go to original source... Go to PubMed...
    7. Fölster-Holst R, Pape M, Buss YL, et al. Low prevalence of the intrinsic form of atopic dermatitis among adult patients. Allergy. 2006; 61(5): 629-632. Go to original source... Go to PubMed...
    8. Bergmann RL, Edenharter G, Bergmann KE, et al. Atopic dermatitis in early infancy predicts allergic airway disease at 5 years. Clin Exp Allergy. 1998; 28(8): 965-970. Go to original source... Go to PubMed...
    9. Bozek A, Fisher A, Filipowska B, et al. Clinical features and immunological markers of atopic dermatitis in elderly patients. Int Arch Allergy Immunol. 2012; 157(4): 372-378. Go to original source... Go to PubMed...
    10. Katsarou A, Armenka M. Atopic dermatitis in older patients: particular points. J Eur Acad Dermatol Venereol. 2011; 25(1): 12-18. Go to original source... Go to PubMed...
    11. Mortz C, Andersen K. New aspects in allergic contact dermatitis. Curr Opin Allergy Clin Immunol. 2008; 8(5): 428-432. Go to original source... Go to PubMed...
    12. Wollenberg A, Oranje M, Deleuran D, et al. EFTAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. J Eur Acad Dermatol Venereol. 2016; 30(5): 729-747. Go to original source... Go to PubMed...
    13. Luger T, Boguniewicz M, Carr W, et al. Pimecrolismus in atopic dermatitis consensus on safety and the need to allow use in infants. Pediatr Allergy Immunol 2015; 26: 306-315. Go to original source... Go to PubMed...
    14. D'Erme AM, Romanelli M, Chiricozi A. Spotlight on dupilumab in the treatment of atopic dermatitis: design, development, and potential place in therapy. Drug Design, Development and Therapy. 2017; 11: 1473-1480. Go to original source... Go to PubMed...
    15. Brodská P, Panzner P, Pizinger K, et al. IgE-mediated sensitization to malassezia in atopic dermatitis: more common in male patients and in head and neck type. Dermatitis 2014; 25(3): 120-126. Go to original source... Go to PubMed...
    16. Back O, Bartosik J. Systemic ketoconazole for yeast allergic patients with atopic dermatitis. J Eur Acad Dermatol Venereol. 2001; 15: 34-38. Go to original source... Go to PubMed...
    17. Svejgaard E, Larsen PO, Deleuran M, et al. Treatment of head and neck dermatitis comparing itraconazole 200 mg and 400 mg daily for 1 week with placebo. J Eur Acad Dermatol Venereol. 2004; 18: 445-449. Go to original source... Go to PubMed...

    Return to the content


    Dermatology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.